PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Drug-eluting stents demonstrate better outcomes after 1 year than bare metal stents

Study finds lower risks of heart attack, death with individualized medication therapy post-stent

2014-03-31
(Press-News.org) WASHINGTON (March 31, 2014) — Use of drug-eluting stents is associated with a lower risk of major cardiovascular events at one year compared to bare metal stents when followed by an individualized course of blood-thinning medication among patients previously thought to be uncertain candidates for drug-eluting stents due to their heightened risk of bleeding or blood clots, according to research presented at the American College of Cardiology's 63rd Annual Scientific Session.

Positive study findings for patients receiving a shorter than currently recommended course of blood thinners may call into question existing guidelines for a more prolonged anti-platelet therapy following placement of drug-eluting stents, which points to the need for a more personalized approach, according to authors.

This multinational, single-blinded trial involved 1,606 patients who were randomly assigned to receive a specific type of drug-eluting stent (Zotarolimus-eluting stent) or a bare metal stent. The purpose of the study was to assess whether implantation of the drug-eluting stent followed by an individualized course of dual anti-platelet therapy – a combination of aspirin and an anti-platelet that thins the blood to prevent clots – would decrease the incidence of 12-month major adverse cardiovascular events compared to implantation with a bare metal stent among patients classified as uncertain candidates for drug-eluting stents. A significantly higher number of patients in the bare metal stent group had major adverse cardiovascular events at one year, including all-cause death, non-fatal heart attacks or any procedures to re-open the artery.

"Given the assumed risks, we were surprised by the lower rate of heart attack and blood clots among our drug-eluting stent patients," said Marco Valgimigli, M.D., Ph.D., cardiologist and associate professor, Erasmus University Medical Center in the Netherlands, and lead investigator of the study. "For the first time, we have handled a drug-eluting stent as we would a bare metal stent in terms of the duration and intensity of anti-platelet therapy and have still shown the superior safety and efficacy of the drug-eluting stent."

A total of 140 or 17.5 percent of patients with the drug-eluting stent had a major cardiovascular event in the first year compared with 178 or 22.1 percent of patients implanted with the bare metal stent. Patients with the drug-eluting stent also had lower rates of heart attack (2.9 compared to 8.1 percent) and procedures to re-open the artery (5.9 compared to 10.7 percent). This group also had lower rates of blood clots around the stent (2.0 compared to 4.1 percent). The rate of bleeding did not differ between groups.

Patients were enrolled at 20 sites in Italy, Switzerland, Portugal and Hungary. All were undergoing percutaneous coronary intervention with stent implantation. Adult patients who met any one of the three criteria to be uncertain candidates for drug-eluting stents were randomly assigned to receive bare metal or drug-eluting stents. To qualify as "uncertain" candidates for drug-eluting stents, patients in the study had to either have a high risk of blood clots, high risk of bleeding and/or low risk of restenosis – the artery becoming blocked again. Patients at a low risk of restenosis were included because the risk of blood clots associated with drug-eluting stents – along with the assumed risk of bleeding from the prolonged course of blood thinners taken afterward – may, in fact, outweigh benefits of this type of stent for these patients.

The majority of patients (95.4 percent) took some course of dual anti-platelet therapy after stent placement, 96.7 percent with aspirin and clopidogrel and the remaining 3.3 percent with aspirin and either prasugrel or ticagrelor. Duration of therapy was dictated by patients' individual risk factors and spanned from no treatment to six to 12 months, with a median of 32 days. Patients who were not eligible for dual anti-platelet therapy were treated with either aspirin or an anti-platelet alone. This protocol represents a departure from current guidelines that recommend the use of dual anti-platelet therapy for six to 12 months after the placement of a drug-eluting stent.

Bare metal stents are metal mesh tubes inserted into clogged arteries to prop them open after they are widened through angioplasty. Scar tissue grows around the stent and holds it in place, but sometimes an overgrowth of tissue can cause the artery to become blocked. This may require the patient to have additional procedures to re-open the artery.

Drug-eluting stents are coated with medication to help prevent scar tissue from growing and to keep the artery smooth and open. Although these stents reduce restenosis rates, they have also been linked to a higher incidence of blood clots around the stent, leading to the current guidelines on prolonged dual anti-platelet therapy after they are placed.

Authors caution that the results of this study pertain to the Zotarolimus-eluting stent and may not apply to other types of drug-eluting stents. According to Valgimigli, additional research is needed to determine whether the personalized dual anti-platelet therapy tested in this study can be safely implemented in patients using other types of drug-eluting stents. He also suggests that a longer follow-up study be conducted to confirm results of this study over time.

INFORMATION: Support for the study was provided by Medtronic, Minneapolis.

The ACC's Annual Scientific Session brings together cardiologists and cardiovascular specialists from around the world each year to share the newest discoveries in treatment and prevention. Follow @ACCMediaCenter and #ACC14 for the latest news from the meeting.

The American College of Cardiology is a nonprofit medical society comprised of 47,000 physicians, surgeons, nurses, physician assistants, pharmacists and practice managers. The College is dedicated to transforming cardiovascular care, improving heart health and advancing quality improvement, patient-centered care, payment innovation and professionalism. The ACC also leads the formulation of important cardiovascular health policy, standards and guidelines. It bestows credentials upon cardiovascular specialists, provides professional education, supports and disseminates cardiovascular research, and operates national registries to measure and promote quality care. For more information, visit CardioSource.org.


ELSE PRESS RELEASES FROM THIS DATE:

Never say never in the nano-world

Never say never in the nano-world
2014-03-31
This news release is available in German. Objects with sizes in the nanometer range, such as the molecular building blocks of living cells or nanotechnological devices, are continuously exposed to random collisions with surrounding molecules. In such fluctuating environments the fundamental laws of thermodynamics that govern our macroscopic world need to be rewritten. An international team of researchers from Barcelona, Zurich and Vienna found that a nanoparticle trapped with laser light temporarily violates the famous second law of thermodynamics, something that ...

New human trial shows stem cells are effective for failing hearts

2014-03-31
WASHINGTON (March 31, 2014) — Patients with severe ischemic heart disease and heart failure can benefit from a new treatment in which stem cells found in bone marrow are injected directly into the heart muscle, according to research presented at the American College of Cardiology's 63rd Annual Scientific Session. "Our results show that this stem cell treatment is safe and it improves heart function when compared to placebo," said Anders Bruun Mathiasen, M.D., research fellow in the Cardiac Catherization Lab at Rigshospitalet University Hospital Copenhagen, and lead investigator ...

Real-world heart procedure results consistent with scientific research

2014-03-31
WASHINGTON (March 31, 2014) — The first one-year outcomes data of transcatheter heart valve replacement (TAVR) in nearly all U.S. patients undergoing this procedure shows that real-world outcomes are comparable to or slightly better than those found in clinical trials, according to registry data presented at the American College of Cardiology's 63rd Annual Scientific Session. However, specific baseline characteristics of patients undergoing TAVR are associated with differing degrees of death and survival and may be important considerations for patient counseling and shared ...

Newly discovered molecule may offer hope for immune disorders and runaway inflammation

2014-03-31
A new research discovery published in the April 2014 issue of the Journal of Leukocyte Biology may open the door to new therapies that help treat immune disorders or curb runaway inflammation. Specifically, scientists have discovered a molecule that can induce cell death (apoptosis) in a key type of immune cell (dendritic cells). With this understanding, it may be possible to develop new therapies that essentially shut down dendritic cell activity, and thereby reducing an immune reaction. "We hope that our findings provide better understanding of immune regulation, which ...

NASA releases images of X-class solar flare

NASA releases images of X-class solar flare
2014-03-31
The sun emitted a significant solar flare, peaking at 1:48 p.m. EDT March 29, 2014, and NASA's Solar Dynamics Observatory captured images of the event. Solar flares are powerful bursts of radiation. Harmful radiation from a flare cannot pass through Earth's atmosphere to physically affect humans on the ground, however -- when intense enough -- they can disturb the atmosphere in the layer where GPS and communications signals travel. To see how this event impacted Earth, please visit NOAA's Space Weather Prediction Center at http://spaceweather.gov, the U.S. government's ...

Stats show growth of breast lifts outpacing implants 2 to 1

Stats show growth of breast lifts outpacing implants 2 to 1
2014-03-31
VIDEO: New statistics from the American Society of Plastic Surgeons show that since 2000, breast lift procedures have grown by 70 percent, twice the rate of breast implants. According to the... Click here for more information. ARLINGTON HEIGHTS, Ill., March 31, 2014 – New statistics released today by the American Society of Plastic Surgeons (ASPS) show that breast lift procedures are growing at twice the rate of breast implant surgeries. Since 2000, breast lifts have grown by ...

Comparison of drug-releasing stents show similar safety outcomes after 2 years

2014-03-31
A comparison of the safety of biodegradable polymer biolimus-eluting stents vs durable polymer everolimus-eluting stents finds similar outcomes for measures including death and heart attack after two years, according to a JAMA study released online to coincide with presentation at the 2014 American College of Cardiology Scientific Sessions. Recent studies have raised concerns about the safety of biodegradable polymer drug-eluting stents (BP-DES) compared with durable polymer everolimus-eluting stents (DP-EES). The NOBORI Biolimus-Eluting vs XIENCE/PROMUS Everolimus-Eluting ...

Six new Dracula ants from Madagascar: Minor workers become queens in Mystrium

Six new Dracula ants from Madagascar: Minor workers become queens in Mystrium
2014-03-31
Six new species of Dracula ants from the Malagasy region have been discovered by scientists at the California Academy of Sciences. The discoveries, by postdoctoral fellow Masashi Yoshimura from Japan and curator of entomology Brian L. Fisher, represent a completely new twist in the typically rigid caste system of ants, where anatomy is typically destiny. The study was published in the open access journal ZooKeys. "The genus Mystrium is the most mysterious group within the bizarre Dracula ants," said Yoshimura. Mystrium species have unique features such as long, spatulate ...

Study further illuminates heart-healthy benefits of Mediterranean diet

2014-03-31
(WASHINGTON, March 31, 2014) – New research further illuminates the heart-healthy benefits of the Mediterranean diet, tying the eating plan to lower levels of platelets and white blood cells, two markers of inflammation. Inflammation has an association with greater risk of heart attack and stroke. Study, results are published online today in Blood, the Journal of the American Society of Hematology (ASH). The Mediterranean diet, characterized by generous servings of foods such as greens, whole grains, fish, and olive oil, has long been hailed as a heart-healthy eating ...

Scientists discover a number of novel genetic defects which cause oesophageal cancer

2014-03-31
A team of scientists from the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore and National University Cancer Institute Singapore (NCIS), and their collaborators from the Cedars-Sinai Medical Centre, UCLA School of Medicine, demonstrated that a number of novel genetic defects are able to induce oesophageal cancer. The research group, led by Professor H. Phillip Koeffler, Senior Principal Investigator at CSI Singapore and Deputy Director of NCIS, has conducted a successful comprehensive genomic study of oesophageal squamous ...

LAST 30 PRESS RELEASES:

Echidnapus identified from an ‘Age of Monotremes’

Semaglutide may protect kidney function in individuals with overweight or obesity and cardiovascular disease

New technique detects novel biomarkers for kidney diseases with nephrotic syndrome

Political elites take advantage of anti-partisan protests to disrupt politics

Tiny target discovered on RNA to short-circuit inflammation, UC Santa Cruz researchers find

Charge your laptop in a minute? Supercapacitors can help; new research offers clues

Scientists discover CO2 and CO ices in outskirts of solar system

Theory and experiment combine to shine a new light on proton spin

PKMYT1, a potential ‘Achilles heel’ of treatment resistant ER+ breast cancers with the poorest prognosis

PH-binding motifs as a platform for drug design: Lessons from protease-activated receptors (PARs)

Virginia Tech researcher creates new tool to move tiny bioparticles

On repeat: Biologists observe recurring evolutionary changes, over time, in stick insects

Understanding a broken heart

Genetic cause of rare childhood immune disorders discovered

With wobbling stars, astronomers gauge mass of 126 exoplanets and find 15 new ones

High H5N1 influenza levels found in mice given raw milk from infected dairy cows

Study finds discreet shipping used to sell e-cigarettes to minors

African scientists call for equitable research partnerships to advance microbiome research

How COVID-19 'breakthrough' infections alter your immune cells

Virginia Tech entomologist sheds light on 250-year-old mystery of the German cockroach

Advancing skin science: explore Skin Ageing & Challenges 2024 Strategic Topics in Malta this November

Controlling water, transforming greenhouse gases

MSK Research Highlights, May 24, 2024

ASCO: Large precision oncology study identifies differences in prostate cancer genomics among a racially and ethnically diverse cohort of U.S. veterans

ASCO: Combination therapy significantly improves outcomes for patients with metastatic colorectal cancer

Euclid space mission releases first scientific results and new images of the cosmos

Sociodemographic heterogeneity in the associations of social isolation with mortality

COVID-19 admission rates and changes in care quality in us hospitals

Preterm and early-term delivery after heat waves in 50 US metropolitan areas

Research spotlight: Virtual scribes reduced physicians’ time spent on electronic health records

[Press-News.org] Drug-eluting stents demonstrate better outcomes after 1 year than bare metal stents
Study finds lower risks of heart attack, death with individualized medication therapy post-stent